Approval of Spravato, granted following FDA priority review, was based on the results ... 7.6 percent of patients taking placebo. Spravato nasal spray is administered by the patient under the ...
Johnson & Johnson has priced its new Spravato nasal spray for treatment-resistant depression ... The Institute for Clinical and Economic Review (ICER) has published its final report on Spravato ...
This treatment is delivered through a nasal spray and relies not on ... The FDA fast-tracked Spravato’s approval through its Priority Review process after receiving results from a randomized ...
Johnson & Johnson has announced that the U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray as the first ... followed a priority review and was based on positive ...
The Food and Drug Administration (FDA) approved Johnson & Johnson's ketamine-derived nasal spray to help millions of U.S. patients suffering from severe depression. Spravato, approved as a ...
The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato ... The FDA's approval of Spravato followed a priority review process based on extensive clinical ...
WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults ... FDA priority review, was based on the results ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback